Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.

British journal of haematology - 1 Sept 2022

Greiner Jochen, Goetz Marlies, Schuler Patrick J, Bulach Christiane, Hofmann Susanne, Schrezenmeier Hubert, Dӧhner Harmut, Schneider Vanessa, Guinn Barbara-Ann

Abstract excerpt

Nucleophosmin1 (NPM1) is one of the most commonly mutated genes in AML and is often associated with a favourable prognosis. Immune responses play an increasing role in AML treatment decisions; however, the role of immune checkpoint inhibition is still not clear. To address this, we investigated specific immune responses against NPM1, and three other leukaemia-associated antigens (LAA), PRAME, Wilms' tumour 1 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Checkpoint Inhibitors
Share to Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nivolumab

Share to Nucleophosmin

Share to Programmed Cell Death 1 Receptor

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 35799423
DOI: 10.1111/bjh.18326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.PMID 35799423Read ↗

Immunotherapeutic Potential of Mutated NPM1 for the Treatment of AMLSemantic proximity Read ↗

Different Immunotherapeutic Combinations Enhance Specific T Cell Immune Responses Against Leukemic Cells, as well as Leukemic Progenitor and Stem Cells, in Acute Myeloid LeukemiaSemantic proximity Read ↗

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemiaSemantic proximity Read ↗

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative NeoplasmsSemantic proximity Read ↗

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)Semantic proximity Read ↗

Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.Semantic proximity Read ↗

Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT.Semantic proximity Read ↗

Development of a flow cytometric method to detect the presence of mutated nucleophosmin 1 in acute myeloid leukemia.Semantic proximity Read ↗

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosminSemantic proximity Read ↗

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AMLSemantic proximity Read ↗

Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.